Cargando…
Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer
Local immunotherapy resurfaces in the field of cancer as a potential way to cure localized and metastatic disease with limited toxic effects. We have recently demonstrated that local administration of agonistic CD40 antibodies can cure localized as well as disseminated bladder neoplasms. This approa...
Autores principales: | Sandin, Linda C, Tötterman, Thomas H, Mangsbo, Sara M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962505/ https://www.ncbi.nlm.nih.gov/pubmed/24701374 http://dx.doi.org/10.4161/onci.27400 |
Ejemplares similares
-
Kick-starting the cancer-immunity cycle by targeting CD40
por: Ellmark, P, et al.
Publicado: (2015) -
ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer
por: Mangsbo, Sara M, et al.
Publicado: (2013) -
Understanding the influence of the tumor microenvironment on macrophage responses to CD40 agonists
por: Luheshi, Nadia, et al.
Publicado: (2014) -
Pre-clinical development of the human CD40 agonistic antibody ADC-1013
por: Norlén, Per, et al.
Publicado: (2015) -
Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity
por: Thomas, Lawrence J, et al.
Publicado: (2014)